Obinutuzumab in Chinese Real-world Patients With iNHL

Not yet recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

July 20, 2026

Conditions
Lymphomas Non-Hodgkin's B-Cell
Interventions
DRUG

Obinutuzumab

obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.

Trial Locations (25)

Unknown

Changzhou No.2 People's Hospital, Changzhou

The First People's hospital of Changzhou, Changzhou

Huai'an First People's hospital, Huai'an

Jiangyin People's Hospital, Jiangyin

Jingjiang People's Hospital, Jingjiang

The first people's hospital of Lianyungang, Lianyungang

The second people's hospital of Lianyungang, Lianyungang

Jiangsu Province Hospital of Chinese Medicine, Nanjing

Jiangsu Province Hospital, Nanjing

Nanjing Drum Tower Hospital, Nanjing

Nanjing Jiangning Hospital, Nanjing

Nantong Tumor Hospital, Nantong

Affiliated Hospital of Nantong University, Nanyang

The Second Affiliated Hospital of Soochow University, Suzhou

Jiangsu Taizhou People's Hospital, Taizhou

Affiliated Hospital of Jiangnan University, Wuxi

Wuxi People's Hospital, Wuxi

Wuxi Second People's Hospital, Wuxi

Yancheng No.1 People's Hospital, Yancheng

Yancheng Third People's Hospital, Yancheng

Subei People's Hospital, Yangzhou

Yixing People's Hospital, Yixing

Zhangjiagang First People's Hospital, Zhangjiagang

Affiliated Hospital of Jiangsu University, Zhenjiang

Zhenjiang First People's Hospital, Zhenjiang

All Listed Sponsors
lead

Affiliated Hospital of Nantong University

OTHER

NCT05968001 - Obinutuzumab in Chinese Real-world Patients With iNHL | Biotech Hunter | Biotech Hunter